Research profile
CJC-1295
CJC-1295 mimics growth hormone-releasing hormone. The published study used a long-acting version.
- Early human biomarker studies
- Evaluation only
Amnavero
CJC-1295
What the research found
In early studies in healthy adults, one administration of the long-acting compound increased mean growth hormone levels for at least six days. Mean IGF-1 also increased.
What remains uncertain
Changes in hormone levels leave clinical benefit and long-term safety unanswered. The specific formulation matters when comparing results.